Showing results (1-10 of 263) with videos related to
Sort By:
Pageof 27
Nature Clinical Practice. Endocrinology & Metabolism|August 25, 2006
Severe hypertriglyceridemia with a history of treatment failureWarren H Capell, Robert H EckelCurrent Diabetes Reports|August 11, 2006
Treatment of hypertriglyceridemiaWarren H Capell, Robert H EckelThe American Journal of Cardiology|December 6, 2006
Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitusTeri L Hernandez, Warren H Capell, Pamela Wolfe, et al.Journal of Clinical Lipidology|February 5, 2011
Plant sterols added to combination statin and colesevelam hydrochloride therapy failed to lower low-density lipoprotein cholesterol concentrationsSunny A Linnebur, Warren H Capell, Joseph J Saseen, et al.American Journal of Physiology. Endocrinology and Metabolism|July 15, 2010
Fatty acids increase glucose uptake and metabolism in C2C12 myoblasts stably transfected with human lipoprotein lipaseWarren H Capell, Isabel R Schlaepfer, Pamela Wolfe, et al.Journal of Lipid Research|April 18, 2003
Increased expression of the SNARE accessory protein Munc18c in lipid-mediated insulin resistanceIsabel R Schlaepfer, Leslie K Pulawa, Luis D M C-B Ferreira, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|February 18, 2003
Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemiaWarren H Capell, Christopher A DeSouza, Paul Poirier, et al.The Journal of Clinical Endocrinology and Metabolism|May 7, 2010
Approach to the patient who is intolerant of statin therapyRobert H EckelThe Proceedings of the Nutrition Society|March 9, 2007
Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVDRobert H EckelEthnicity & Disease|November 20, 2012
CVD health factors and CVD risk factors: state of the science, emerging priorities part 2: obesity preventionRobert H EckelPageof 27